Browsing Category
Pharma Industry News
4723 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition
Gilead Sciences agrees to acquire Ouro Medicines for up to $2.175bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Read the full strategic analysis.
GlycoNex and Nippon Kayaku team up to advance next-generation ADC candidate GNX201-ADC in solid tumours
GlycoNex (4168) and Nippon Kayaku advance GNX201-ADC, a protease-activated ADC targeting solid tumours. Discover what this deal means for oncology. Read more.
Can Insilico Medicine’s PandaClaw agentic AI platform accelerate pharma software licensing revenue growth in 2026?
Insilico Medicine launches PandaClaw, an agentic AI tool that lets biologists run autonomous multi-omics drug discovery analysis. Read what it means for pharma.
Why Dai Nippon Printing chose Hyderabad for its second overseas R&D hub as 7912 retreats from 52-week highs
Dai Nippon Printing (TSE: 7912) opens an IIT Hyderabad R&D base for EV wireless charging and pharma APIs. Read the full strategic analysis.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
Torrent Pharma (NSE: TORNTPHARM) enters GLP-1 market with Sembolic and Semalix as over 40 rivals chase semaglutide patent expiry windfall
Torrent Pharmaceuticals launches India's first generic oral semaglutide alongside injectable Sembolic as GLP-1 patent expires. What the pricing and strategy mean. Read more.
Bristol Myers Squibb (NYSE: BMY) expands Opdivo into frontline Hodgkin lymphoma, strengthening immuno-oncology leadership
Bristol Myers Squibb expands Opdivo in Hodgkin lymphoma. Discover how this reshapes treatment strategy, competition, and long-term oncology trends.
Dizal’s sunvozertinib beats chemo in phase 3 first-line NSCLC trial, opening path to new drug applications
Dizal's sunvozertinib beats platinum chemo in WU-KONG28 phase 3 first-line EGFR exon 20 NSCLC trial. What this means for patients, rivals and investors. Read more.
Aelis Farma’s AEF0217 enters critical Phase 2B trial—can it become the first drug for Down syndrome cognition?
Aelis Farma launches Phase 2B trial for AEF0217 in Down syndrome—could this CB1-targeting drug finally deliver a breakthrough? Read more.
Novo Nordisk strengthens obesity leadership with Wegovy HD FDA approval and higher-efficacy profile
Novo Nordisk secures FDA approval for Wegovy HD, boosting weight loss efficacy. Discover what this means for the obesity drug market.